To Predict the Requirement of Pharmacotherapy by OGTT Glucose Levels in Women with GDM Classified by the IADPSG Criteria
Table 1
Characteristics of the study population.
GDM-LSI ()
GDM-PT ()
value
Age (years)
108
31.5 ± 5.9
95
34.6 ± 5.9
<0.001
BMI (kg/m2)
107
27.8 ± 6.4
94
30.1 ± 6.9
0.014
Fertility treatment
108
6 (5.6%)
95
8 (8.4%)
0.421
Gravidity (count)
108
3.0 (2.0–4.0)
95
3.0 (2.0–5.0)
0.029
Gravidity (>1)
108
87 (80.6%)
95
83 (87.4%)
0.189
Parity (count)
108
1.0 (0.0–2.0)
95
1.0 (1.0–2.5)
0.054
Parity (≥1)
108
73 (67.6%)
95
74 (77.9%)
0.101
pGDM
102
19 (18.6%)
87
34 (39.0%)
0.002
G0 (mg/dl)
105
90.0 ± 10.8
95
98.8 ± 19.2
<0.001
G60 (mg/dl)
101
173.2 ± 29.5
87
189.0 ± 30.8
<0.001
G120 (mg/dl)
98
129.7 ± 29.0
88
140.4 ± 33.9
0.021
Gmean (mg/dl)
98
130.6 ± 15.2
87
141.7 ± 20.3
<0.001
Week diagnosis
108
28.0 (26.4–30.3)
95
27.7 (25.6–29.4)
0.032
Week treatment start
—
95
31.1 (28.0–33.3)
BW (pct)
108
50.5 (24.0–70.5)
95
50.0 (26.0–86.0)
0.427
LGA
108
12 (11.1%)
95
21 (22.1%)
0.034
Data are mean ± standard deviations or median and interquartile range (IQR) for pregnant women affected by GDM and treated with lifestyle modification (GDM-LSI) or requiring pharmacologic treatment (GDM-PT). BMI: pregestational body mass index; pGDM: previous pregnancy with gestational diabetes mellitus; G0: fasting plasma glucose; G60: plasma glucose 60 min after oral glucose load; G120: plasma glucose 120 min after oral glucose load; BW: birth weight; LGA: large for gestational age offspring.
